These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 27111637)

  • 21. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.
    Michaelson JS; Demarest SJ; Miller B; Amatucci A; Snyder WB; Wu X; Huang F; Phan S; Gao S; Doern A; Farrington GK; Lugovskoy A; Joseph I; Bailly V; Wang X; Garber E; Browning J; Glaser SM
    MAbs; 2009; 1(2):128-41. PubMed ID: 20061822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.
    Abdiche YN; Yeung YA; Chaparro-Riggers J; Barman I; Strop P; Chin SM; Pham A; Bolton G; McDonough D; Lindquist K; Pons J; Rajpal A
    MAbs; 2015; 7(2):331-43. PubMed ID: 25658443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates.
    Datta-Mannan A; Witcher DR; Tang Y; Watkins J; Jiang W; Wroblewski VJ
    Drug Metab Dispos; 2007 Jan; 35(1):86-94. PubMed ID: 17050651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A modular IgG-scFv bispecific antibody topology.
    Orcutt KD; Ackerman ME; Cieslewicz M; Quiroz E; Slusarczyk AL; Frangioni JV; Wittrup KD
    Protein Eng Des Sel; 2010 Apr; 23(4):221-8. PubMed ID: 20019028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach.
    Betts A; Keunecke A; van Steeg TJ; van der Graaf PH; Avery LB; Jones H; Berkhout J
    MAbs; 2018 Jul; 10(5):751-764. PubMed ID: 29634430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longitudinal evaluation of the biodistribution and cellular internalization of the bispecific CD3xTRP1 antibody in syngeneic mouse tumor models.
    Sandker GGW; Middelburg J; Wilbrink E; Molkenboer-Kuenen J; Aarntzen E; van Hall T; Heskamp S
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37899133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity.
    Mandrup OA; Ong SC; Lykkemark S; Dinesen A; Rudnik-Jansen I; Dagnæs-Hansen NF; Andersen JT; Alvarez-Vallina L; Howard KA
    Commun Biol; 2021 Mar; 4(1):310. PubMed ID: 33686177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fabs-in-tandem immunoglobulin is a novel and versatile bispecific design for engaging multiple therapeutic targets.
    Gong S; Ren F; Wu D; Wu X; Wu C
    MAbs; 2017 Oct; 9(7):1118-1128. PubMed ID: 28692328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies.
    Shen J; Vil MD; Jimenez X; Iacolina M; Zhang H; Zhu Z
    J Biol Chem; 2006 Apr; 281(16):10706-14. PubMed ID: 16481314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32).
    Ball ED; Guyre PM; Mills L; Fisher J; Dinces NB; Fanger MW
    J Hematother; 1992; 1(1):85-94. PubMed ID: 1365020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Construction and production of an IgG-Like tetravalent bispecific antibody, IgG-single-chain Fv fusion.
    Lu D; Zhu Z
    Methods Mol Biol; 2014; 1060():185-213. PubMed ID: 24037843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.
    Souders CA; Nelson SC; Wang Y; Crowley AR; Klempner MS; Thomas W
    MAbs; 2015; 7(5):912-21. PubMed ID: 26018774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes.
    van der Flier A; Liu Z; Tan S; Chen K; Drager D; Liu T; Patarroyo-White S; Jiang H; Light DR
    PLoS One; 2015; 10(4):e0124930. PubMed ID: 25905473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Engineering of stable bispecific antibodies targeting IL-17A and IL-23.
    Mabry R; Lewis KE; Moore M; McKernan PA; Bukowski TR; Bontadelli K; Brender T; Okada S; Lum K; West J; Kuijper JL; Ardourel D; Franke S; Lockwood L; Vu T; Frank A; Appleby MW; Wolf A; Reardon B; Hamacher NB; Stevens B; Lewis P; Lewis KB; Gilbertson DG; Lantry M; Julien SH; Ostrander C; Chan C; Byrnes-Blake K; Brody J; Presnell S; Meengs B; Levin SD; Snavely M
    Protein Eng Des Sel; 2010 Mar; 23(3):115-27. PubMed ID: 20022918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies.
    Stracke J; Emrich T; Rueger P; Schlothauer T; Kling L; Knaupp A; Hertenberger H; Wolfert A; Spick C; Lau W; Drabner G; Reiff U; Koll H; Papadimitriou A
    MAbs; 2014; 6(5):1229-42. PubMed ID: 25517308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys.
    Datta-Mannan A; Witcher DR; Lu J; Wroblewski VJ
    MAbs; 2012; 4(2):267-73. PubMed ID: 22377715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49.
    Chauhan SC; Jain M; Moore ED; Wittel UA; Li J; Gwilt PR; Colcher D; Batra SK
    Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):264-73. PubMed ID: 15791435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity.
    Dong J; Sereno A; Snyder WB; Miller BR; Tamraz S; Doern A; Favis M; Wu X; Tran H; Langley E; Joseph I; Boccia A; Kelly R; Wortham K; Wang Q; Berquist L; Huang F; Gao SX; Zhang Y; Lugovskoy A; Martin S; Gouvis H; Berkowitz S; Chiang G; Reff M; Glaser SM; Hariharan K; Demarest SJ
    J Biol Chem; 2011 Feb; 286(6):4703-17. PubMed ID: 21123183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge.
    Li B; Tesar D; Boswell CA; Cahaya HS; Wong A; Zhang J; Meng YG; Eigenbrot C; Pantua H; Diao J; Kapadia SB; Deng R; Kelley RF
    MAbs; 2014; 6(5):1255-64. PubMed ID: 25517310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
    Gurbaxani B; Dostalek M; Gardner I
    Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.